ADRB2-Targeting Therapies for Prostate Cancer

There is accumulating evidence that β-2 adrenergic receptor (ADRB2) signaling contributes to the progression and therapy resistance of prostate cancer, whereas availability of clinically tested β-blocker propranolol makes this pathway especially attractive as potential therapeutic target. Yet even i...

Descripción completa

Detalles Bibliográficos
Autor principal: Kulik, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468358/
https://www.ncbi.nlm.nih.gov/pubmed/30871232
http://dx.doi.org/10.3390/cancers11030358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468358/
https://www.ncbi.nlm.nih.gov/pubmed/30871232
http://dx.doi.org/10.3390/cancers11030358

Ejemplares similares